Results Of the 5564 pts who met the inclusion criteria (median age: 57 yrs), 63% were post-menopausal and 52% had stage I eBC at diagnosis...This study confirmed long-term toxicity of ET, particularly pain. Better management of symptoms and supportive interventional strategies are needed to further improve QoL in eBC.

over 2 years ago

Clinical • HEOR

HER-2 (Human epidermal growth factor receptor 2)

HR positive • HER-2 negative • HR positive + HER-2 negative

eritoran (E5564)

almost3years

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov)

P3, N=10000, Recruiting, UMC Utrecht | Trial completion date: Dec 2025 --> Feb 2028 | Trial primary completion date: Dec 2023 --> Feb 2026

almost 3 years ago

Trial completion date • Trial primary completion date

imatinib • hydroxychloroquine • simvastatin • Actemra IV (tocilizumab) • Kevzara (sarilumab) • Kineret (anakinra) • eritoran (E5564)

4years

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov)

P3, N=10000, Recruiting, UMC Utrecht | Phase classification: P4 --> P3 | N=7100 --> 10000 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Dec 2023

4 years ago

Phase classification • Enrollment change • Trial completion date • Trial primary completion date

imatinib • hydroxychloroquine • simvastatin • Actemra IV (tocilizumab) • Kevzara (sarilumab) • Kineret (anakinra) • eritoran (E5564)

over5years

Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis. (PubMed, Biosci Rep)

The array data of GSE41368, GSE43795, GSE55643, and GSE41369 were downloaded from Gene Expression Omnibus (GEO) database...miR-135b, miR-221, miR-21, miR-27a, miR-199b-5p, miR-143, miR-196a, miR-655, miR-455-3p, miR-744 and hub genes predicted poor OS of PDAC. An integrative bioinformatics analysis identified several hub genes that may serve as potential biomarkers or targets for early diagnosis and precision target treatment of PDAC.

over 5 years ago

Journal

MET (MET proto-oncogene, receptor tyrosine kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MIR21 (MicroRNA 21) • MIR221 (MicroRNA 221) • MIR27A (MicroRNA 27a) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MIR135B (MicroRNA 135b)

eritoran (E5564)

almost6years

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov)

P4, N=7100, Recruiting, MJM Bonten | Trial completion date: Jun 2022 --> Dec 2023

almost 6 years ago

Trial completion date

imatinib • hydroxychloroquine • simvastatin • Actemra IV (tocilizumab) • Kevzara (sarilumab) • Kineret (anakinra) • eritoran (E5564)

over7years

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov)

P4, N=6800, Recruiting, MJM Bonten | N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016

over 7 years ago

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date

imatinib • hydroxychloroquine • simvastatin • Actemra IV (tocilizumab) • Kevzara (sarilumab) • Kineret (anakinra) • eritoran (E5564)